An sabunta ta ranar 10 ga Yuni, 2022, bisa ga shawarwarin wucin gadi da aka sabunta.
Kungiyar kwararru ta WHO Strategic Advisory Group (SAGE) ta ba da shawarwarin wucin gadi don amfani da rigakafin Sinopharm kan COVID-19.Wannan labarin yana ba da taƙaitaccen shawarwarin na wucin gadi;kuna iya samun damar cikakken takardar jagora anan.
Ga abin da kuke buƙatar sani.
Wanene za a iya yi wa allurar?
Maganin yana da lafiya kuma yana da tasiri ga duk mutane masu shekaru 18 zuwa sama.Dangane da taswirar ba da fifiko na WHO da Tsarin Kimar WHO, ya kamata a ba da fifiko ga manya, ma'aikatan kiwon lafiya da masu rigakafin rigakafi.
Ana iya ba da rigakafin Sinopharm ga mutanen da suka yi COVID-19 a baya.Amma mutane na iya zaɓar jinkirta yin rigakafin na tsawon watanni 3 bayan kamuwa da cutar.
Ya kamata a yi wa mata masu ciki da masu shayarwa allurar?
Bayanan da ake samu kan maganin COVID-19 na Sinopharm a cikin mata masu juna biyu bai isa ba don tantance ingancin rigakafin ko haɗarin da ke da alaƙa da allurar a cikin ciki.Duk da haka, wannan maganin alurar riga kafi ne wanda ba a kunna ba tare da adjuvant wanda ake amfani dashi akai-akai a cikin wasu alluran rigakafi da yawa tare da bayanan lafiya mai kyau, ciki har da mata masu juna biyu.Ana sa ran ingancin maganin COVID-19 na Sinopharm a cikin mata masu juna biyu zai yi kama da wanda aka gani a cikin mata marasa ciki masu shekaru iri daya.
A cikin wucin gadi, WHO ta ba da shawarar yin amfani da rigakafin COVID-19 na Sinopharm a cikin mata masu juna biyu lokacin da fa'idodin rigakafin ga mace mai ciki ya fi haɗarin haɗari.Don taimakawa mata masu juna biyu yin wannan kima, yakamata a ba su bayanai game da haɗarin COVID-19 a cikin ciki;yuwuwar fa'idodin allurar rigakafi a cikin mahallin annoba na gida;da kuma iyakokin halin yanzu na bayanan aminci a cikin mata masu juna biyu.WHO ba ta ba da shawarar gwajin ciki kafin a yi alurar riga kafi ba.WHO ba ta ba da shawarar jinkirta daukar ciki ko yin la'akari da dakatar da ciki ba saboda allurar rigakafi.
Ana sa ran tasirin rigakafin zai kasance iri ɗaya a cikin mata masu shayarwa kamar sauran manya.WHO ta ba da shawarar yin amfani da rigakafin COVID-19 na Sinopharm a cikin mata masu shayarwa kamar sauran manya.WHO ba ta ba da shawarar daina shayarwa ba bayan alurar riga kafi.
Wanene ba a ba da shawarar maganin ba?
Mutanen da ke da tarihin anaphylaxis ga kowane ɓangaren maganin bai kamata su sha ba.
Duk wanda ke da zafin jiki sama da 38.5ºC ya kamata ya jinkirta yin rigakafin har sai ya daina jin zazzabi.
lafiya?
SAGE ta tantance cikakkun bayanai kan inganci, aminci da ingancin maganin kuma ya ba da shawarar amfani da shi ga mutane masu shekaru 18 zuwa sama.
An iyakance bayanan aminci ga mutane sama da shekaru 60 (saboda ƙaramin adadin mahalarta gwaji na asibiti).Duk da yake ba za a iya tsammanin bambance-bambance a cikin bayanan amincin maganin rigakafin a cikin tsofaffi idan aka kwatanta da matasa masu tasowa, ƙasashe da ke tunanin yin amfani da wannan maganin a cikin mutanen da suka girmi shekaru 60 ya kamata su kula da sa ido kan aminci.
Yaya ingancin maganin yake?
Babban gwaji na 3 na ƙasa da yawa ya nuna cewa allurai 2, waɗanda aka gudanar a cikin tazara na kwanaki 21, suna da inganci na 79% a kan kamuwa da cutar SARS-CoV-2 na alamun alamun kwanaki 14 ko fiye bayan kashi na biyu.Ingancin allurar rigakafin kamuwa da asibiti ya kai kashi 79%.
Ba a ƙirƙira gwajin ba kuma an ƙarfafa shi don nuna inganci a kan cutar mai tsanani a cikin mutane masu kamuwa da cuta, a cikin ciki, ko a cikin mutane masu shekaru 60 zuwa sama.Mata ba su da yawa a cikin shari'ar.Tsawon tsaka-tsakin lokaci na bin diddigin da ake samu a lokacin nazarin shaida shine kwanaki 112.
Akwai wasu gwaji guda biyu masu inganci amma har yanzu ba a samu bayanai ba.
Menene shawarar sashi?
SAGE yana ba da shawarar yin amfani da maganin rigakafin Sinopharm azaman 2 allurai (0.5 ml) da aka ba a cikin muscularly.
SAGE ya ba da shawarar cewa a ba da kashi na uku, ƙarin kashi na rigakafin Sinopharm ga mutane masu shekaru 60 zuwa sama a matsayin wani ɓangare na ƙarin jerin farko.Bayanai na yanzu baya nuna buƙatar ƙarin kashi a cikin mutane a ƙarƙashin shekaru 60.
SAGE ya ba da shawarar cewa ya kamata a ba wa mutanen da ba su da rigakafi mai tsanani da matsakaicin ƙarin kashi na rigakafin.Wannan ya faru ne saboda gaskiyar cewa wannan ƙungiyar ba ta da yuwuwar ba da isasshiyar amsa ga alluran rigakafin bin daidaitattun jerin allurar rigakafin farko kuma suna cikin haɗarin cutar COVID-19 mai tsanani.
WHO ta ba da shawarar tazara na makonni 3-4 tsakanin kashi na farko da na biyu na jerin farko.Idan an yi amfani da kashi na biyu kasa da makonni 3 bayan na farko, adadin ba ya buƙatar maimaitawa.Idan an jinkirta gudanar da kashi na biyu fiye da makonni 4, ya kamata a ba da shi a farkon damar da za a iya.Lokacin ba da ƙarin kashi zuwa sama da 60s, SAGE yana ba da shawarar ƙasashe yakamata su fara yin niyya don haɓaka ɗaukar hoto na 2 a cikin wannan adadin, sannan kuma a ba da kashi na uku, farawa da ƙungiyoyin tsofaffi.
Shin ana ba da shawarar adadin kuzari don wannan maganin?
Za a iya la'akari da kashi na ƙarfafawa watanni 4 - 6 bayan kammala jerin allurar rigakafin farko, farawa tare da mafi girman ƙungiyoyin amfani da fifiko, daidai da taswirar ba da fifiko na WHO.
Ana gane fa'idodin rigakafin haɓakar haɓakawa sakamakon haɓakar shaidar tasirin tasirin rigakafin rigakafin kamuwa da cuta mai sauƙi da asymptomatic SARS-CoV-2 akan lokaci.
Ana iya amfani da ko dai homologous (samfurin rigakafin daban-daban zuwa Sinopharm) ko heterologous (ƙananan ƙarar Sinopharm) ana iya amfani da allurai.Wani bincike a Bahrain ya gano cewa haɓakar haɓakar nau'ikan nau'ikan ya haifar da mafi girman martanin rigakafi idan aka kwatanta da haɓakar ɗabi'a.
Shin za a iya 'haɗuwa da daidaitawa' da sauran alluran rigakafi?
SAGE yana karɓar allurai iri-iri na WHO EUL COVID-19 a matsayin cikakken jerin farko.
Don tabbatar da daidai ko ingantaccen rigakafi ko ingancin rigakafin ko dai na WHO EUL COVID-19 mRNA alluran rigakafi (Pfizer ko Moderna) ko na WHO EUL COVID-19 vectored alluran (AstraZeneca Vaxzevria / COVISHIELD ko Janssen) za a iya amfani dashi azaman kashi na biyu biyo bayan kashi na farko tare da rigakafin Sinopharm ya dogara da samuwan samfur.
Yana hana kamuwa da kamuwa da cuta?
A halin yanzu babu wani takamaiman bayanai da ke da alaƙa da tasirin Sinopharm akan watsa SARS-CoV-2, kwayar cutar da ke haifar da cutar COVID-19.
A halin da ake ciki, WHO tana tunatar da buƙatar kulawa da ƙarfafa matakan kiwon lafiyar jama'a waɗanda ke aiki: rufe fuska, nesantar jiki, wanke hannu, tsabtace numfashi da tari, guje wa taron jama'a da tabbatar da isassun iska.
Shin yana aiki da sabbin bambance-bambancen kwayar cutar SARS-CoV-2?
A halin yanzu SAGE yana ba da shawarar yin amfani da wannan rigakafin, bisa ga taswirar fifikon WHO.
Yayin da sabbin bayanai ke samuwa, WHO za ta sabunta shawarwarin yadda ya kamata.Har yanzu ba a tantance wannan maganin ba a yanayin yaɗuwar bambance-bambancen damuwa.
Yaya wannan maganin ya kwatanta da sauran alluran rigakafin da aka riga aka yi amfani da su?
Ba za mu iya kwatanta alluran kai-da-kai ba saboda hanyoyi daban-daban da aka ɗauka wajen tsara binciken daban-daban, amma gabaɗaya, duk allurar rigakafin da suka samu Jerin Amfani da Gaggawa na WHO suna da matuƙar tasiri wajen hana cututtuka masu tsanani da asibiti sakamakon COVID-19. .
Lokacin aikawa: Juni-15-2022